Purpose Immunotherapy has started to transform the treatment of triple-negative breast
cancer (TNBC), in part due to the unique immunogenicity of this breast cancer subtype. This …

Introduction The treatment landscape of early triple-negative breast cancer (TNBC) has
recently expanded after the Food and Drug Administration (FDA) approval of …

Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy
characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) …

Objective To assess the efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy for
early-stage triple-negative breast cancer (TNBC) patients with different clinical …

Purpose The use of immune checkpoint inhibitors in combination with chemotherapy for the
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …

Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative
breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …

The lack of effective therapies for metastatic triple‐negative breast cancer (mTNBC)
highlights the need for the development of novel treatment strategies. The cornerstone of …